XBiotech Inc. (XBIT): Price and Financial Metrics

XBiotech Inc. (XBIT): $3.70

0.05 (-1.33%)

POWR Rating

Component Grades








Add XBIT to Watchlist
Sign Up

Industry: Biotech




#252 of 359

in industry

XBIT Price/Volume Stats

Current price $3.70 52-week high $6.69
Prev. close $3.75 52-week low $3.00
Day low $3.60 Volume 11,800
Day high $3.80 Avg. volume 42,702
50-day MA $3.98 Dividend yield N/A
200-day MA $4.35 Market Cap 112.62M

XBIT Stock Price Chart Interactive Chart >


  • Growth is the dimension where XBIT ranks best; there it ranks ahead of 47.28% of US stocks.
  • XBIT's strongest trending metric is Growth; it's been moving down over the last 108 days.
  • XBIT ranks lowest in Momentum; there it ranks in the 7th percentile.

XBIT Stock Summary

  • The ratio of debt to operating expenses for XBIOTECH INC is higher than it is for about merely 0.22% of US stocks.
  • XBIT's price/sales ratio is 399.74; that's higher than the P/S ratio of 98.98% of US stocks.
  • Revenue growth over the past 12 months for XBIOTECH INC comes in at -96.35%, a number that bests just 0.85% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to XBIT, based on their financial statements, market capitalization, and price volatility, are RVMD, CKPT, PNT, CRSP, and NRIX.
  • XBIT's SEC filings can be seen here. And to visit XBIOTECH INC's official web site, go to www.xbiotech.com.

XBIT Valuation Summary

  • In comparison to the median Healthcare stock, XBIT's price/earnings ratio is 118.52% lower, now standing at -4.5.
  • Over the past 104 months, XBIT's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for XBIT.

Stock Date P/S P/B P/E EV/EBIT
XBIT 2023-11-03 64.2 0.6 -4.5 0.6
XBIT 2023-11-02 67.0 0.6 -4.7 0.4
XBIT 2023-11-01 66.1 0.6 -4.6 0.5
XBIT 2023-10-31 64.2 0.6 -4.5 0.6
XBIT 2023-10-30 61.5 0.5 -4.3 0.9
XBIT 2023-10-27 61.5 0.5 -4.3 0.9

XBIT Growth Metrics

    The year over year cash and equivalents growth rate now stands at -3.36%.
  • Its 2 year price growth rate is now at -58.56%.
  • Its 5 year price growth rate is now at 62.32%.
XBIT's revenue has moved up $8,210,000 over the prior 67 months.

The table below shows XBIT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 8.21 -19.286 -36.164
2022-06-30 11.049 -16.661 -26.767
2022-03-31 14.044 62.513 -20.241
2021-12-31 18.394 69.445 -17.414
2021-09-30 19.163 70.813 -12.785
2021-06-30 25.193 81.698 -12.05

XBIT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XBIT has a Quality Grade of D, ranking ahead of 11.91% of graded US stocks.
  • XBIT's asset turnover comes in at 0.071 -- ranking 289th of 682 Pharmaceutical Products stocks.
  • QLGN, GTHX, and CPHI are the stocks whose asset turnover ratios are most correlated with XBIT.

The table below shows XBIT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.071 0.391 -0.195
2021-03-31 0.102 0.248 -0.138
2020-12-31 0.124 0.215 -0.116
2020-09-30 0.082 0.166 7.794
2020-06-30 0.070 0.188 10.040
2020-03-31 0.039 0.237 14.665

XBiotech Inc. (XBIT) Company Bio

XBiotech Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing “True Human™” monoclonal antibodies for treating various different diseases. The company was founded in 2005 and is based in Austin, Texas.

XBIT Latest News Stream

Event/Time News Detail
Loading, please wait...

XBIT Latest Social Stream

Loading social stream, please wait...

View Full XBIT Social Stream

Latest XBIT News From Around the Web

Below are the latest news stories about XBIOTECH INC that investors may wish to consider to help them evaluate XBIT as an investment opportunity.

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled Phase I dose escalation clinical study has been enrolled. XBiotech discovered, manufactures, and is conducting this clinical study of Hutrukin. The primary objective of the Phase I study is to evaluate safety and pharmacokinetics of Hutru

Yahoo | September 26, 2023

Individual investors account for 50% of XBiotech Inc.'s (NASDAQ:XBIT) ownership, while insiders account for 35%

Key Insights The considerable ownership by individual investors in XBiotech indicates that they collectively have a...

Yahoo | September 16, 2023

XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-controlled clinical study for Natrunix in combination with chemotherapy for treating pancreatic cancer. Natrunix is indistinguishable from a naturally occurring antibody present in a healthy human. Natrunix binds and neutralizes a potent substance, a so called cytokine known as interleukin-1a (IL-1a),

Yahoo | August 30, 2023

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis. Natrunix blocks a key cause of inflammation involved in pain and joint destruction in rheumatoid arthritis (RA). The primary endpoint of the Phase II is the American College of Rheumatology (ACR) 20% Response (ACR 20) rate at 12 weeks. Secondary and exp

Yahoo | August 8, 2023

The past three years for XBiotech (NASDAQ:XBIT) investors has not been profitable

It is a pleasure to report that the XBiotech Inc. ( NASDAQ:XBIT ) is up 60% in the last quarter. But that doesn't...

Yahoo | July 25, 2023

Read More 'XBIT' Stories Here

XBIT Price Returns

1-mo -7.50%
3-mo -24.80%
6-mo -27.59%
1-year 21.31%
3-year -80.92%
5-year -17.41%
YTD 5.41%
2022 -68.46%
2021 -28.88%
2020 -16.15%
2019 267.42%
2018 28.93%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!